The Food and Drug Administration yesterday issued an update for health care providers treating patients at risk for sudden cardiac arrest using a Zoll LifeVest 4000 wearable cardioverter defibrillator. In January, FDA alerted patients and providers that the device may fail to deliver a life-saving shock if not replaced soon after displaying a particular “call for service” message code. The update provides additional information regarding the manufacturer’s efforts to remedy the potential hazard as well as recommendations for providers.
 

Related News Articles

Headline
Civica Rx, the not-for-profit generic drug company, officially opened its headquarters last week in Lehi, Utah.
Headline
The Food and Drug Administration plans to revise its 2016 draft compounding guidance for hospital and health system pharmacies.
Headline
The Food and Drug Administration Friday released draft guidance on how drug developers can apply for the agency’s Competitive Generic Therapies designation.
Headline
Members of the pharmaceutical distribution supply chain, including dispensers such as hospitals and pharmacies, can apply through March 11 to participate in a…
Headline
The U.S. District Court for the Western District of Pennsylvania has entered a consent decree prohibiting Ranier’s Rx Laboratory Inc. from manufacturing or…
Headline
The Food and Drug Administration Friday warned physicians and patients who use medical devices to monitor levels of the blood thinner warfarin that certain…